Table 3.

12/24-month persistence rates and 95% confidence intervals (CI) for BTs psoriasis therapy

	Total				BT-naïve
	ADL	IFX	SCK	UST	ADL	IFX	SCK	UST
Number of patients	42	52	21	90	37	48	13	79
12-month persistence rate ± 95% CI	45.9% ± 15.5%	53.1% ± 14.7%	74.2% (95% CI not available)	79.8% ± 9.1%	46.8% ± 16.6%	53.0% ± 14.9%	55.4% (95% CI not available)	79.4% ± 9.9%
24-month persistence rate ± 95% CI	45.9 ± 15.5%	41.1% ± 15.4%	74.2% (95% CI not available)	73.4% ± 10.9%	46.8 ± 16.6%	41.0% ± 15.5%	55.4% (95% CI not available)	71.9 ± 12.2%
p-value of log-rank test (versus UST)	< 0.001	< 0.001	0.254	–	< 0.001	< 0.001	0.006	–
p-value of wilcoxon test (versus UST)	< 0.001	0.001	0.163	–	< 0.001	0.001	0.004	–

ADL Adalimumab, IFX Infliximab, SCK Secukinumab, UST Ustekinumab. 95% CI of SCK was not available because of too small number of patients